MarketPulse

ATTC platform

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Unveils Novel Cancer Therapy Data Ahead of AACR 2026 Meeting

HUTCHMED to present preclinical data on first-in-class PI3K/PIKK therapy and updated Phase Ib/II surufatinib combination trial results at AACR Annual Meeting 2026.
HCMoncologycancer therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Launches Global Trial for Dual-Action Tumor Therapy HMPL-A580

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.
HCMclinical developmentsolid tumors